
Quintiles president to chair Idis
pharmafile | September 13, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | IDIS, Quintiles, thomis
Former Quintiles president Jeff Thomis has been appointed to the role of chairman at Idis.
In his new role, Thomis will work with the Idis Board and leadership team to deliver the company’s future growth plans by increasing access to medicines worldwide.
Thomis spent 15 years at clinical research organisation Quintiles, as president of Global Clinical Development Services and chairman of the American Management Board.
He takes a wealth of pharma and clinical research strategic leadership experience to Idis, and the firm says his expertise lies in helping to grow international businesses in a rapidly changing healthcare environment.
Thomis said: “I am delighted to be appointed chairman of Idis. I look forward to working with the Board to ensure we drive the growth of the organisation whilst maintaining our patient focussed approach to developing and delivering the best managed access programmes.”
Related Content

Quintiles to merge with IMS Health
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement …

Clinigen buys Idis for £225 million
UK speciality pharma group Clinigen is paying £225 million to acquire the Surrey-based unlicensed supplier …
Contract research news in brief
Icon offers $52m for CCH’s clinical services division, plus updates from PPD, Aptuit, Argenta, Quintiles …






